- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04193592
Efficacy and Safety of Pirfenidone Treatment in HPS-ILD (PEARL)
Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Tamra Perez, BSN
- Número de teléfono: 1-215-955-9181
- Correo electrónico: tamra.perez@jefferson.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University
-
Investigador principal:
- Jesse Roman, MD
-
Contacto:
- Tamra Perez
- Número de teléfono: 215-955-9181
- Correo electrónico: Tamra.Perez@jefferson.edu
-
-
-
-
-
Mayaguez, Puerto Rico, 00680
- Mayaguez Medical Center
-
Contacto:
- Rosa Roman, MD
- Número de teléfono: 7874676080
-
Investigador principal:
- Rosa Roman, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Probable or definite diagnosis of HPS based on confirmed genetic mutation or clinical picture characterized by oculo-cutaneous albinism, bleeding disorder, and possible colitis and ILD.
- Diagnosis of ILD supported by clinically indicated HRCT prior to Screening, and presence of fibrotic abnormality affecting more than 5% of the lung parenchyma, with or without traction bronchiectasis or honeycombing, on Screening
- No features supporting an alternative diagnosis (e.g., infection)
- Change in pre-bronchodilator FVC (measured in liters) between Screening (Visit 1) and
Baseline (Visit 2) must be a < 10% relative difference, calculated as:
100%*[absolute value (Screening FVC - Baseline FVC)/Screening FVC
- Stable dose (at least three months at the time of Screening) of corticosteroids.
- No cytotoxic, immunosuppresive agents, cytokine-modulating, or receptor antagonists agents are allowed (including but not limited to azathioprine, cyclophosphamide, cyclosporine, etanercept, iloprost, infliximab, methotrexate, mycophenolate mofetil, nintedanib, tacrolimus, tetrathiomolybdate, TNF-α inhibitors, rituximab, abatacept, tofacitintib, tociluzimab).
- Able to understand and sign a written informed consent form
Exclusion Criteria:
- Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, in the opinion of the investigator
- Cigarette smoking within 3 months of Screening or unwilling to avoid tobacco products throughout the study
- History of clinically significant environmental exposure known to cause pulmonary fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds
- Concurrent presence of other interstitial lung disease, including but not limited to radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer
- Concurrent presence of other pleuropulmonary manifestations inconsistent with HPS- ILD
- Presence of pleural effusion occupying more than 10% of the hemithorax on Screening HRCT
- Clinical diagnosis of a connective tissue disease or overlap syndrome (including but not limited to rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus)
- Coexistent clinically significant COPD/emphysema or asthma in the opinion of the site principle investigator
- Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
- Any history of malignancy diagnosed within 5 years of screening, other than basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or low grade cervical carcinoma in situ.
- History of severe hepatic impairment or end-stage liver disease
- History of end-stage renal disease requiring dialysis
- History of unstable or deteriorating cardiac or disease, myocardial infarction within the previous year, heart failure within the last 3 years, or cardiac arrhythmia requiring drug therapy
- Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the 52 weeks of treatment.
- A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
For men who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
- With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 118 days after the last dose of pirfenidone.
- Men must refrain from donating sperm during this same period.
- Investigational therapy, defined as any drug that has not been approved for marketing for any indication in the country of the participating site including pirfenidone, at the time of Screening
- History of alcohol or substance abuse in the past 2 years, at the time of Screening
- Family or personal history of long QT syndrome
Any of the following liver function test criteria above specified limits:
- Total bilirubin above the upper limit of normal (ULN), excluding patients with Gilbert's syndrome; aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN
- Creatinine clearance (CrCl <30) mL/min, calculated using the Cockcroft-Gault formula
- Electrocardiogram (ECG) with a QTcB interval >500 msec at Screening
- Prior use of pirfenidone or known hypersensitivity to any of the components of study treatment
Use of any of the following therapies within 28 days before Screening:
- Investigational therapy, defined as any drug that has not been approved for marketing for any indication in the country of the participating site
- Fluvoxamine
- Sildenafil (daily use). Note: intermittent use for erectile dysfunction is allowed
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Oral Pirfenidone 2403 mg per day
Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day.
Pirfenidone will be supplied in 267 mg capsules.
|
Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID.
Dose may be reduced to manage an adverse event.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in Forced Vital Capacity (FVC)
Periodo de tiempo: baseline, 6 months, 12 months
|
The incidence of decline in percent predicted FVC of 10 % or greater from baseline measured at 6 and 12 months
|
baseline, 6 months, 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in Forced Vital Capacity (FVC)
Periodo de tiempo: week 52
|
1.
The Incidence of decline from baseline in percent predicted FVC of 10% or greater during the 52 week treatment period.
|
week 52
|
Change in Diffusion Capacity (DLCO)
Periodo de tiempo: week 52
|
2. The Incidence of decline from baseline in percent predicted DLCO of 15% or greater during the 52 week treatment period.
|
week 52
|
Incidence of Treatment Emergent Adverse Events
Periodo de tiempo: week 52
|
3. The number of participants with and number of treatment emergent adverse events reported by the participant will be collected.
|
week 52
|
Incidence of Treatment Emergent Serious Adverse Events
Periodo de tiempo: week 52
|
4. The number of participants with and number of treatment-emergent serious adverse events reported by the participants will be collected.
|
week 52
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jesse Roman, MD, Thomas Jefferson University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades metabólicas
- Enfermedades de la piel
- Enfermedades de las vías respiratorias
- Enfermedades de los ojos
- Enfermedad
- Enfermedades hematológicas
- Trastornos de la coagulación de la sangre, hereditarios
- Trastornos hemorrágicos
- Enfermedades Genéticas Congénitas
- Enfermedades De La Piel Genéticas
- Enfermedades De Los Ojos Hereditarias
- Trastornos de la coagulación de la sangre
- Metabolismo, errores congénitos
- Trastornos de las plaquetas sanguíneas
- Metabolismo de aminoácidos, errores congénitos
- Trastornos de la pigmentación
- Hipopigmentación
- Albinismo
- Albinismo Oculocutáneo
- Deficiencia de reserva de plaquetas
- Síndrome
- Enfermedades pulmonares
- Enfermedades Pulmonares Intersticiales
- Síndrome de Hermanski-Pudlak
- Efectos fisiológicos de las drogas
- Agentes del sistema nervioso periférico
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Agentes antineoplásicos
- Pirfenidona
Otros números de identificación del estudio
- 14172/2019
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .